Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky(Nektar Therapeutics (United States)), John R. Desjarlais(Xencor (United States)), Aaron K. Chamberlain(University of California, Berkeley), Thomas J. Sproule(Jackson Laboratory), Greg A. Lazar(Xencor (United States)), Irene Leung(Xencor (United States)), Holly M. Horton(Xencor (United States)), Sher Karki(Xencor (United States)), Derry C. Roopenian(Jackson Laboratory)
Cited by 654
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan
|The Journal of Experimental Medicine|2003|641
The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs
|The Journal of Immunology|2003|456
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403